Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04943068
Other study ID # KD-BMT-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 10, 2021
Est. completion date December 31, 2022

Study information

Verified date May 2022
Source Kwang Dong Pharmaceutical co., ltd.
Contact Soo Woong Kim, Dr
Phone 02-2072-2426
Email swkim@snu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).


Recruitment information / eligibility

Status Recruiting
Enrollment 186
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender Female
Age group 19 Years and older
Eligibility [Main Inclusion Criteria] - Has met diagnostic criteria for HSDD for at least 6 months - Is willing and able to understand and comply with all study requirements - Has a normal pelvic examination at screening [Main Exclusion Criteria] - Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results - Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial

Study Design


Related Conditions & MeSH terms

  • Hypoactive Sexual Desire Disorder
  • Hypokinesia
  • Sexual Dysfunctions, Psychological

Intervention

Drug:
Bremelanotide
Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
Placebo
Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Kwang Dong Pharmaceutical co., ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to End of Study in the desire domain from the FSFI Baseline up to End of Study(8weeks)
Secondary Change from baseline to End of Study in FSDS-DAO (Item 13) Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of Study in the FSDS-DAO Total Score Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of study in the total FSFI score based on the 19 questions The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome. Baseline up to End of Study(8weeks)
Secondary Change in mean Level of Sexual Arousal from FSEP-R Q6 Baseline up to End of Study(8weeks)
Secondary Change in mean Satisfaction with Sexual Arousal from FSEP-R Q7. Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of study in the scored time spent being concerned by difficulty with sexual arousal as measured by the FSDS-DAO Q14. Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of study in the arousal domain from the FSFI Q3 through Q6. Baseline up to End of Study(8weeks)
Secondary Change from Baseline to End of study in the total number of SSEs. Baseline up to End of Study(8weeks)
Secondary Change from baseline in the desire domain from the FSFI Q1 and Q2 using all available double-blind data (visit 4, 5) Baseline up to End of Study(8weeks)
Secondary Change from baseline in the score for feeling bothered by low sexual desire as measured by the FSDS -DAO Q13 using all available double-blind data(visit 4, 5) Baseline up to End of Study(8weeks)
Secondary Change from baseline in the number of SSEs associated with study drug using the entire 8 weeks of the double-blind phase. Baseline up to End of Study(8weeks)
See also
  Status Clinical Trial Phase
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT01432665 - Lybrido for Female Sexual Dysfunction Phase 2
Terminated NCT00551785 - Surveillance Study of Women Taking Intrinsa® Phase 4
Completed NCT03232801 - A Mindfulness-based Intervention for Older Women With Low Sexual Desire N/A
Recruiting NCT04179734 - Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Phase 4
Terminated NCT02770768 - Effects of Flibanserin on the Pre- and Post-menopausal Female Brain N/A
Completed NCT01235754 - Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Phase 3
Completed NCT03287232 - Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Phase 3
Completed NCT00384046 - Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen Phase 3
Completed NCT00331123 - Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Phase 3
Completed NCT03463707 - BP101 for Adults With Female Sexual Dysfunction Phase 3
Completed NCT01208038 - Testosterone Patch's Effects on the Cardiovascular System and Libido Phase 4
Completed NCT00657501 - Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Phase 3
Completed NCT04336891 - Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
Completed NCT01382719 - Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Phase 2
Recruiting NCT00916396 - Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder N/A
Completed NCT00034021 - Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Phase 2
Completed NCT00338312 - Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Phase 3
Completed NCT00331214 - Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Phase 3
Recruiting NCT02968342 - Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women Phase 4